BioCentury
ARTICLE | Financial News

Ahead of Phase III mucositis study, Galera raises $150M

September 19, 2018 6:17 PM UTC

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase III trial of GC4419 to treat severe oral mucositis in patients with head and neck cancer.

Also participating were new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital and Tekla Capital Management, as well as existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures...

BCIQ Company Profiles

Galera Therapeutics Inc.